La cadena de opciones muestra datos clave de las opciones de acciones de Lixte Biotechnology a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Lixte Biotechnology..

Lixte Biotechnology (NASDAQ:LIXT) Bolsa, Cadena de Opciones

Lixte Biotech Hldgs

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology Holdings Inc

Lixte Biotechnology Holdings, Inc. - Warrants

These Healthcare stocks are trading higher:-Ibio Inc (IBIO) stock is trading at $3.38, an increase of $2.23, or 185.96%, on high volume.  Ibio Inc gets a Sentiment Score of Very Bullish from InvestorsObserver.  -Lixte Biotechnology Holdings Inc (LIXT) stock is trading at $3.40, an increase of $1.14, or 48.23%, on high volu

Healthcare Stocks on the Move Wednesday: IBIO, LIXT, STOK, NUVB, OGI, BIOR, GOSS, MRAI

Lixte stock soars on preclinical data for lead drug LB-100

Lixte Biotechnology Holdings Inc (LIXT) is lower by Thursday morning, with the stock decreasing -6.82% in pre-market trading to 3.28. LIXT's short-term technical score of 36 indicates that the stock has traded less bullishly over the last month than 64% of stocks on the market. In the Biotechnology industry, which ranks 10

Lixte Biotechnology Holdings Inc (LIXT) Down 6.82% in Premarket Trading

Lixte Biotechnology Holdings Inc (LIXT) is down -11.24%% today. LIXT has an Overall Score of 14. Find out what this means to you and get the rest of the rankings on LIXT!See Full LIXT ReportLIXT stock closed at $3.38 and is down -$0.38 during pre-market trading. Pre-market tends to be more volatile due to significantly low

Should You Buy Lixte Biotechnology Holdings Inc (LIXT) Stock Monday Morning?

MSTR, BIOR and ARBK among pre-market losers

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Lixte Biotech Hldgs</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/lixt-stock-quote/"><strong>LIXT</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Lixte Biotech Hldgs reported earnings per share of -43 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/lixt-stock-earnings-lixte-biotech-hldgs-for-q1-of-2024/">LIXT Stock Earnings: Lixte Biotech Hldgs Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

LIXT Stock Earnings: Lixte Biotech Hldgs Reported Results for Q1 2024

Lixte Biotechnology appoints Jan Schellens as CMO

An announcement from Lixte Biotechnology Holdings (LIXT) is now available. In a significant corporate update, the Company has announced the appoint...

Lixte Biotechnology Appoints New Chief Medical Officer

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Lixte Biotech Hldgs</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/lixt-stock-quote/"><strong>LIXT</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Lixte Biotech Hldgs reported earnings per share of -45 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/lixt-stock-earnings-lixte-biotech-hldgs-for-q2-of-2024/">LIXT Stock Earnings: Lixte Biotech Hldgs Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

LIXT Stock Earnings: Lixte Biotech Hldgs Reported Results for Q2 2024

WallachBeth Capital is sole placement agent. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. ...

Lixte Biotechnology files to sell units, no amount given

ADTX

ARBK

AVTX

BDRX

BIOR

CLSK

CZOO

GOSS

GRDI

GUTS

IBIO

IINN

LIXT

MCAF

MRAI

MSTR

NUVB

OCEA

STOK

Press Releases

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

Biotech

Events

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

LIXTE Biotechnology Provides Update On Recent Activities and Developments

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

News

"Stocks Key Trendlines: PRSO, PFIE, SHPH, BKYI, LIXT on the Verge of Breakthroughs"

Comments

Lixte Biotechnology

Lixte Biotechnology (LIXT) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL